Visão geral da empresa
A clinical-stage biotechnology entity, Unicycive Therapeutics, Inc., focuses on identifying, developing, and commercializing therapies designed to address significant unmet medical needs within the United States healthcare landscape. The company operates specifically within the broader Healthcare sector and the specialized Biotechnology industry, a classification that signifies its primary engagement in research, development, and potential commercialization of pharmaceutical candidates rather than mature product sales. As of the latest reported data, the entity holds a market capitalization of $162.78M and employs a workforce of 21 individuals, reflecting the lean operational structure typical of early-stage biotech firms. These specific valuation and personnel figures indicate that the company is currently in a capital-intensive development phase where market cap represents investor sentiment on future potential rather than realized revenue generation, as the firm has not yet achieved substantial annual revenue streams. The small employee count relative to the market cap suggests a high reliance on external capital or strategic partnerships to advance its drug candidates, such as UNI 494, which is being developed as a pro-drug of Nicorandil for the treatment of acute kidney injury.
Saúde financeira
The financial statements for Unicycive Therapeutics, Inc. reveal a company in a loss-making stage with a net income of $-26,555,000 and an EBITDA of $-29,483,000 over the trailing twelve-month period. Since the reported revenue is N/A, the substantial negative net income highlights a cost structure dominated by research and development expenses, administrative overhead, and clinical trial costs that currently exceed any generated income. The free cash flow stands at $-22,924,500, indicating that the company is burning cash rapidly to fund its operations and development pipeline, which limits immediate financial flexibility without external financing or successful commercialization milestones. All three reported margins—gross margin, operating margin, and profit margin—are listed as 0.0%, a metric that, in the context of a clinical-stage biotech with no reported revenue, reflects the absence of operating leverage rather than a failure to manage costs efficiently. On the liability side, the company holds $41.27M in cash against $117,000 in debt, resulting in a debt-to-equity ratio of 0.39, which suggests a balance sheet that is heavily cash-funded with negligible leverage. The current ratio is reported at 2.58, indicating that the company possesses 2.58 times the current assets relative to its current liabilities, thereby maintaining a conservative short-term liquidity position sufficient to cover obligations. Return on Equity is -141.1% and Return on Assets is -45.7%, metrics that mathematically demonstrate the company is currently destroying equity value and utilizing assets to generate losses, which is typical for entities in the pre-revenue phase where management effectiveness is measured by the ability to extend the cash runway rather than profitability.
Avaliação de valorização
Valuation metrics for Unicycive Therapeutics, Inc. present a complex picture due to the lack of earnings, with a trailing P/E ratio listed as N/A and a forward P/E of 0.75. The forward P/E of 0.75 is technically an anomaly for a loss-making company, implying that market pricing models may be utilizing adjusted earnings or that the forward earnings estimate is negligible, suggesting investors are pricing the stock based on future potential rather than current profitability. The price-to-book ratio is 4.73, which indicates that the market values the company at a significant premium of 4.73 times its tangible book value, reflecting high expectations for the future success of its drug candidates despite current losses. Alternative valuation metrics further highlight the lack of traditional earnings power, with the price-to-sales ratio listed as N/A due to the absence of revenue and an EV/EBITDA of -4.12, which confirms the negative earnings multiple derived from the negative EBITDA. The stock trades between a 52-week high of $11.00 and a 52-week low of $3.71, with the current price position relative to this range indicating high volatility and sensitivity to biotech sector developments. The beta value is 1.80, meaning the stock's price volatility is expected to be 1.8 times greater than that of the broader market, signaling that investors should anticipate significant price swings that may be disproportionately influenced by specific clinical trial results or regulatory news.
Growth & Income
Growth metrics for Unicycive Therapeutics, Inc. show revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, consistent with the company's status as a clinical-stage entity without established commercial revenue streams. Since there is no revenue base to compare against, the concept of earnings growing faster or slower than revenue is not applicable in the traditional sense, as the company is currently in a phase of capital deployment rather than scaling operations. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available resources are being retained and reinvested into research, development, and clinical trials rather than distributed to shareholders. This reinvestment strategy is characteristic of biotechnology companies that prioritize long-term product development over short-term income generation, relying on future commercialization of therapies like UNI 494 to eventually generate cash flows for potential shareholder returns.